Introduction
Uveomeningoencephalitides, commonly known as Vogt-Koyanagi-Harada (VKH) disease, are characterized by chronic bilateral granulomatous panuveitis involving the central nervous, auditory and integumentary systems. Case reports were first described by Vogt in 1906 and Koyanagi in 1929 in patients presenting with bilateral anterior uveitis, vitiligo, poliosis, alopecia and dysacousia. This became known as Vogt-Koyanagi syndrome. In 1926 a similar condition was described by Harada, presenting with posterior uveitis, exudative retinal detachment and cerebrospinal fluid pleocytosis. This syndrome was termed Harada's disease. These syndromes are now considered variants of a single entity and are referred to as VKH disease or the uveomeningoencephalitides [1] .
Neurological concomitants of uveitis are not uncommon. In their review of 1450 patients with uveitis, Smith and Rosenbaum [2 ] found that 115 (7.9%) had neurological disease that was considered to be causally related to the eye inflammation. The most frequent neurological associations were VKH disease, primary central nervous system lymphoma, multiple sclerosis and herpes virus infection. These investigators concluded that neurological disease is common among patients attending a uveitis service. The distinctive characteristics of the uveal inflammation may be useful in diagnosing the neurological disease.
Epidemiology
The typical age of onset for VHK disease is 30-40 years, and women are affected more often than men. Because the disease occurs more frequently in pigmented groups [3, 4] , it is likely that certain ethnic groups have genetic backgrounds that predispose them to VKH disease. Specific human leucocyte antigen (HLA) types have been reported to be associated with the disease. Findings from different parts of the world [5, 6] 
Aetiology and pathogenesis
The precise cause of the disease is uncertain, but Tlymphocyte-mediated autoimmunity directed against melanocytes is likely to play an important role [8, 9] . This is supported by the finding that lymphocytes taken from patients with VKH disease multiply when they are exposed to crude extracts of melanocyte [10] . Although the specific peptide target has not been identified, recent animal studies have shown that inoculation of rats with peptides derived from the family of tyrosinase proteins responsible for melanin formation can induce VKH disease-like syndromes [11] . The ultrastructural changes in rat eyes with experimental VKH disease are similar to those in eyes of humans with VKH disease [12 ] .
Pras et al.
[13 ] identified an underlying autoimmune disease in up to 40% of patients with intraocular inflammation. These included spondyloarthropathies, Behçet's disease, sarcoidosis, juvenile chronic arthritis, VKH disease, immune recovery syndrome and uveitis with tubulointerstitial disease. Further support for the hypothesis that VKH disease is an autoimmune syndrome comes from its association with other such diseases, including thyroid disease, rheumatoid arthritis, ulcerative colitis and keratoconjunctivitis sicca [14] [15] [16] [17] . Although it may occur spontaneously, some evidence suggests that sensitization to melanocytic antigens by means of cutaneous injury or viral infection may precipitate the disease [18] [19] [20] . An exogenous factor such as viral infection has been suggested in the pathogenesis of VKH disease by a report of almost simultaneous onset of VKH disease in coworkers, friends and neighbours [21 ] . The presence of anti-SS-A/Ro reactivity in sera from patients with VKH disease and similar histopathological findings in experimental rabbits also suggested a possible shared target autoantigen with ocular onchocerciasis [22 ] . However, the findings of an in-vivo confocal microscopy (IVCM) study of the keratic precipitate (KP) in patients with VKH disease [23 ] favoured a noninfectious origin for uveomeningoencephalitides.
VKH disease was recently reported to occur during interferon-a therapy for chronic hepatitis C [24, 25 ] . Interferon can induce a T-helper-1-type response and alter the expression of major histocompatibility complex class I and II antigens, possibly leading to the development of VKH disease. It is suggested that chronic hepatitis C patients undergoing interferon treatment, especially those with darkly pigmented skin, must be closely monitored for ophthalmological complications over a prolonged period through periodic check-ups of the fundi. This further supports the possibility that VKH disease has an autoimmune nature.
Clinical manifestations and diagnosis
The presenting complaint is usually loss of vision in one or both eyes, eye pain and hearing disturbance. Patients typically exhibit a prodromal aseptic meningitis-like syndrome that may include headache, vertigo, nuchal rigidity, vomiting and low-grade fever. The first attempt to establish diagnostic criteria for VKH took place in 1978 at the annual meeting of the American Uveitis Society [30] . Because the sequential development of these findings often makes prospective studies unfeasible, the diagnostic criteria were recently revised by the First International Workshop on VKH in 1999 [31, 32] . The new criteria take into account the multisystemic nature of VKH disease, with allowance for the different ocular findings that are present in the early and late stages of the disease. A diagnosis of complete VKH disease depends upon the presence of the five criteria listed in Table 1 .
In recent years, several examinations have been reported to be helpful in the diagnosis and follow up of VKH disease, including indocyanine green angiography, ultrasound biomicroscopy, IVCM and optical coherence tomography (OCT). By allowing better visualization of the choroids, indocyanine green angiography has been reported to be a promising tool for diagnosing and monitoring treatment in VKH disease [33, 34] . Ultrasound biomicroscopy is considered helpful in determining disease activity in the anterior segment and in monitoring the clinical course. It may improve evaluation of the efficacy of treatment, especially when the view of the fundus is blocked by synechiae and cataract [35, 36] .
Recently, Wertheim et al.
[23 ] reported the first time using in-vivo confocal microscopy (IVCM) to describe the architecture and heterogeneity keratic precipitates (KP) in uveitis. As documented by IVCM, their findings showed that KPs are markedly heterogeneous and variable. KPs in individual patients are consistent throughout the cornea; the morphological features of KPs change over time; and infectious and noninfectious causes of uveitis appear to be readily distinguishable by using IVCM. KPs may be consistent in specific disease states, and therefore they may have diagnostic importance.
Uveomeningoencephalitides Sheu 325 Our understanding of the pathogenesis of and treatment planning for various vitreoretinal diseases has been revolutionized by the development of OCT. It permits noncontact, cross-sectional imaging of the retina at an axial resolution of 10-15 mm, and enables direct, real-time imaging of the retinal pathology, which could not previously be visualized in vivo. It has been used to evaluate the rapid effects of pulse corticosteroid therapy on the serous retinal detachment found in the acute phase of VKH disease, and to elucidate the nature of serous retinal detachment in VKH disease [37, 38 ] . OCT revealed two patterns of serous retinal detachment: true retinal detachment and intraretinal fluid accumulation in the outer retina. Intraretinal fluid accumulation appeared as an oval space in the outer retina. On fluorescein angiography, the eyes with intraretinal fluid accumulation exhibited more severe dye leakage from the retinal pigment epithelium (Fig. 1) . These findings suggest disruption of the outer blood-retinal barrier, which may allow fluid from the choroids to permeate the intraretinal potential space. This might reflect the severity of the disease. OCT has potential in grading the severity of uveomeningoencephalitides, as a guide to the efficacy of treatment, and as a monitoring tool.
Complications
Complications are the main causes of poor visual outcome. It is primarily during the chronic recurrent phases that patients develop these complications. The most frequently reported complications include cataract, glaucoma and choroidal neovascularization. The first two of these entities may also be caused by corticosteroid therapy. The occurrence of complications is known to be associated with the duration of disease, the number of recurrent episodes of inflammation and the extent of retinal detachment in the acute phase [39, 40 ,41]. Although not listed among the complications, pigmentary changes and generalized atrophy of retina may contribute to impaired visual outcome in some patients [42, 43] .
Although uncommon, some patients will suffer recurrence in the form of chronic anterior uveitis. Increased expression of Fas and Fas ligand mRNA in peripheral blood lymphocytes in VKH disease may be responsible for its perpetuation and recurrence [44 ] .
Another possible vision-threatening complication, subretinal fibrosis, has attracted much attention during the past few years. Although the incidence of this complication varied greatly in different studies, it is generally agreed that presence of subretinal fibrosis is associated with a poor visual prognosis [45, 46] .
Treatments
Although the visual prognosis in VKH disease is generally favourable, outcomes in terms of final visual acuity may vary. The treatment of choice also varies in different parts of the world. Usually, the aim of therapy for VKH disease is to suppress the initial intraocular inflammation with early and aggressive use of systemic corticosteroids. Typically, prednisolone 1-2 mg/kg per day (or equivalent) is used. Cytotoxic/immunosuppressive agents are needed in refractory cases [47] . Systemic corticosteroid therapy is generally accepted as the standard of care for initial therapy, but there is no consensus regarding the optimal route and dosage of administration. For refractory cases, repeated pulse corticosteroid therapy has been suggested. Alternatively, repeated pulse corticosteroid therapy with or without intravenous immunoglobulin therapy has been used [48 ,49 ] . Intravitreal triamcinolone (4 mg) was administered in one study [50 ] , conferring short-term improvement in visual acuity and serous retinal detachment associated with VKH disease. This treatment may permit systemic corticosteroid use to be shortened or even eliminated in selected cases.
Treatment not involving administering large doses of corticosteroids has been reported, with good visual outcome [51] . Considering the side effects of massive doses of corticosteroids, treatment that avoids the use of these agents is a sensible alternative in those cases that are likely to run a benign course. In order to determine which patients will have a benign course, as a treatment guideline, some factors should be recognized in the acute stage of VKH disease. A number of factors are reportedly related to poor visual outcome, including the presence of complications, age at onset, worse visual acuity at presentation, severity of anterior uveitis, extent of exudative retinal detachment, rapid tapering of steroids, interval between symptom and diagnosis, and greater number of recurrences [40 ,52,53] . The development of complications, recurrence and tapering of steroids are not good indicators in the early stage. The influence of age has been reported with controversial results [39,40 ,54-56] . As is usual, early diagnosis and prompt treatment are the key to success. Reports in the literature revealed that those patients who were treated early had better outcomes [52] [53] [54] [55] [56] . In our retrospective study of 31 patients with VKH disease who were diagnosed and treated within 1 month of the onset of ocular symptoms [40 ] , we found that the extent of exudative retinal detachment was significantly correlated with the development of recurrence, complication and final visual outcome. In the acute stage, the extent of exudative retinal detachment might be an important prognostic factor for visual outcome, and might be a useful guide to treatment in the early stages of VKH disease [40 ] . Ethnicity was also postulated to be a significant prognostic factor, but as yet this is not confirmed [57 ] . In their retrospective study of 17 cases, Guenoun et al. [57 ] concluded that VKH disease, in a Caucasian and African population, has a presentation close to that in the Japanese population, but the cutaneous signs are much rarer.
In addition to medical therapy, surgical intervention has been tried in severe cases of bullous retinal detachment, with good results [58] [59] [60] . The advantage of surgical drainage of the subretinal fluid can partly be attributed to the shortened duration of photoreceptor damage, which has been reported to require a significantly longer time than that of other macular functions in some patients with VKH disease [61 ] . Surgical intervention was also advised in cases with complications of VKH, such as cataract and uncontrolled glaucoma. Reports from different groups show that cataract extraction in patients with VKH disease can be safely and successfully performed if there is good preoperative and postoperative control of inflammation, careful surgical planning and meticulous surgical technique. The final visual outcome depends on the posterior segment complications of the syndrome [62, 63 ].
Treatment of choroidal neovascularization in VKH presents a real challenge to the ophthalmologist. Considering its inflammatory nature, therapy works by decreasing the underlying inflammation, which may allow regression of the vascularization. As with choroidal neovascularization in other disease entities, surgical removal of the neovascular membrane may offer some hope, although recurrence is an important issue. Photodynamic therapy with verteporfin has been tried, resulting in regression of choroidal neovascularization, but unpredicted findings involving normal retina in the vicinity of the lesion suggest that further studies are required to assess its usefulness [64] .
Conclusion
Although 
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Hayakawa K, Ishikawa M, Yamaki K. Ultrastructural changes in rat eyes with experimental Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 2004; 48:222-227. Pigmented rats were immunized with tyrosinase family proteins, and the eyes were enucleated after various postinoculation times. Electron microscopy showed thickening of the choroid resulting from the invasion of many lymphocytes and epithelioid-like cells. The melanocytes were surrounded by lymphocytes and had lost their normal spindle shape. Neutrophils and eosinophils were also present in the choroid. These findings are very similar to the changes reported in eyes from patients with VKH disease or sympathetic ophthalmia. The authors reviewed the English medical literature using Medline (1984 Medline ( -2003 employing the terms 'uveitis', 'intraocular inflammation' and 'autoimmune diseases'. An underlying autoimmune disease was identified in up to 40% of patients with intraocular inflammation, and included spondyloarthropathies, Behçets disease, sarcoidosis, juvenile chronic arthritis, VKH syndrome, immune recovery syndrome and uveitis with tubulointerstitial disease.
